-
Something wrong with this record ?
Heat Shock Protein Inhibitor 17-Allyamino-17-Demethoxygeldanamycin, a Potent Inductor of Apoptosis in Human Glioma Tumor Cell Lines, Is a Weak Substrate for ABCB1 and ABCG2 Transporters
N. Pastvova, P. Dolezel, P. Mlejnek
Language English Country Switzerland
Document type Journal Article
Grant support
IGA_LF 2020_025
Palacky University Olomouc
NLK
Directory of Open Access Journals
from 2009
Free Medical Journals
from 2009
PubMed Central
from 2004
Europe PubMed Central
from 2004
ProQuest Central
from 2004-01-01
Open Access Digital Library
from 2004-01-01
Open Access Digital Library
from 2009-01-01
ROAD: Directory of Open Access Scholarly Resources
from 2004
PubMed
33573093
DOI
10.3390/ph14020107
Knihovny.cz E-resources
- Publication type
- Journal Article MeSH
Glioblastoma multiforme (GBM) is the most common primary brain tumor in adults and has a poor prognosis. Complex genetic alterations and the protective effect of the blood-brain barrier (BBB) have so far hampered effective treatment. Here, we investigated the cytotoxic effects of heat shock protein 90 (HSP90) inhibitors, geldanamycin (GDN) and 17-allylamino-17-demethoxygeldanamycin (17-AAG, tanespimycin), in a panel of glioma tumor cell lines with various genetic alterations. We also assessed the ability of the main drug transporters, ABCB1 and ABCG2, to efflux GDN and 17-AAG. We found that GDN and 17-AAG induced extensive cell death with the morphological and biochemical hallmarks of apoptosis in all studied glioma cell lines at sub-micro-molar and nanomolar concentrations. Moderate efflux efficacy of GDN and 17-AAG mediated by ABCB1 was observed. There was an insignificant and low efflux efficacy of GDN and 17-AAG mediated by ABCG2. Conclusion: GDN and 17-AAG, in particular, exhibited strong proapoptotic effects in glioma tumor cell lines irrespective of genetic alterations. GDN and 17-AAG appeared to be weak substrates of ABCB1 and ABCG2. Therefore, the BBB would compromise their cytotoxic effects only partially. We hypothesize that GBM patients may benefit from 17-AAG either as a single agent or in combination with other drugs.
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc21010578
- 003
- CZ-PrNML
- 005
- 20210610134007.0
- 007
- ta
- 008
- 210413s2021 sz f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.3390/ph14020107 $2 doi
- 035 __
- $a (PubMed)33573093
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a sz
- 100 1_
- $a Pastvova, Nikola $u Department of Anatomy, Faculty of Medicine and Dentistry, Palacky University Olomouc, Hnevotinska 3, 77515 Olomouc, Czech Republic
- 245 10
- $a Heat Shock Protein Inhibitor 17-Allyamino-17-Demethoxygeldanamycin, a Potent Inductor of Apoptosis in Human Glioma Tumor Cell Lines, Is a Weak Substrate for ABCB1 and ABCG2 Transporters / $c N. Pastvova, P. Dolezel, P. Mlejnek
- 520 9_
- $a Glioblastoma multiforme (GBM) is the most common primary brain tumor in adults and has a poor prognosis. Complex genetic alterations and the protective effect of the blood-brain barrier (BBB) have so far hampered effective treatment. Here, we investigated the cytotoxic effects of heat shock protein 90 (HSP90) inhibitors, geldanamycin (GDN) and 17-allylamino-17-demethoxygeldanamycin (17-AAG, tanespimycin), in a panel of glioma tumor cell lines with various genetic alterations. We also assessed the ability of the main drug transporters, ABCB1 and ABCG2, to efflux GDN and 17-AAG. We found that GDN and 17-AAG induced extensive cell death with the morphological and biochemical hallmarks of apoptosis in all studied glioma cell lines at sub-micro-molar and nanomolar concentrations. Moderate efflux efficacy of GDN and 17-AAG mediated by ABCB1 was observed. There was an insignificant and low efflux efficacy of GDN and 17-AAG mediated by ABCG2. Conclusion: GDN and 17-AAG, in particular, exhibited strong proapoptotic effects in glioma tumor cell lines irrespective of genetic alterations. GDN and 17-AAG appeared to be weak substrates of ABCB1 and ABCG2. Therefore, the BBB would compromise their cytotoxic effects only partially. We hypothesize that GBM patients may benefit from 17-AAG either as a single agent or in combination with other drugs.
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Dolezel, Petr $u Department of Anatomy, Faculty of Medicine and Dentistry, Palacky University Olomouc, Hnevotinska 3, 77515 Olomouc, Czech Republic
- 700 1_
- $a Mlejnek, Petr $u Department of Anatomy, Faculty of Medicine and Dentistry, Palacky University Olomouc, Hnevotinska 3, 77515 Olomouc, Czech Republic
- 773 0_
- $w MED00184066 $t Pharmaceuticals (Basel, Switzerland) $x 1424-8247 $g Roč. 14, č. 2 (2021)
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/33573093 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y - $z 0
- 990 __
- $a 20210413 $b ABA008
- 991 __
- $a 20210610134006 $b ABA008
- 999 __
- $a ind $b bmc $g 1649865 $s 1130954
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2021 $b 14 $c 2 $e 20210129 $i 1424-8247 $m Pharmaceuticals $n Pharmaceuticals (Basel) $x MED00184066
- GRA __
- $a IGA_LF 2020_025 $p Palacky University Olomouc
- LZP __
- $a Pubmed-20210413